Những podcast Market Access hay nhất (2024)

1
Best practice RWE approaches to support economic modelling for HTA 59:53

3h ago59:53

59:53

How can real-world evidence (RWE) support health technology assessment (HTA)? Can real-world data (RWD) supplement clinical data? How can RWE be used to solve common challenges with treatment comparison? Here, Mtech Access are joined by experts from Arcturis and Delta Hat. Dan Howard (Associate Director – Health Economics, Mtech Access) shares some…

1
NHS winter planning 2024–25 – Engaging with NHS decision-makers through Autumn to Christmas 1:02:50

1d ago1:02:50

1:02:50

How is the NHS preparing for winter? Which challenges are the most pressing for NHS decision-makers? How can industry best engage and support NHS decision-makers in the next few months? In August, Karen Cooper (Senior Consultant – NHS Insight & Interaction, Mtech Access) was joined by Jo Turl (Former Director of Commissioning, Devon ICS) to explore…

1
De-mystifying the NHS – What you need to know about the NHS as a market for your health technology 56:15

1M ago56:15

56:15

Are you a global market access lead looking to understand the challenges faced by your UK affiliates? Or do you work at a national level with responsibility for bringing a new health technology to the NHS in England? In July 2024, Global Whispers and NHS Whispers came together, to bring you an overarching view of what it takes to access the NHS wit…

1
NHS primary care panel – the GP Contract and Operational Planning Guidance 1:02:14

2M ago1:02:14

1:02:14

What can we expect to see in primary care in the NHS given recent policy announcements and ongoing uncertainty? What does the new GP Contract tell us about the future of primary care? What are the biggest challenges facing primary care in 2024–25? In this webinar, Karen Cooper (Senior Consultant – NHS Insight & Interaction, Mtech Access) spoke to a…

1
Engage NHS healthcare decision-makers with RWD 20:55

3M ago20:55

20:55

Discover how data visualisation dashboards can aid field teams in market access discussions with customers. Healthcare leaders look to real-world data (RWD) to inform decisions. Field teams presenting decision-makers with RWD within a well-designed, easy-to-use visualisation can build a case for change, while positioning themselves as a trusted par…

1
Market access and reimbursement in Canada – changes at CADTH 47:43

5M ago47:43

47:43

What do you need to know about the market access and reimbursement landscape in Canada? What changes can we expect at the Canadian Agency for Drugs and Technologies in Health (CADTH) in 2024/2025? In this webinar, Clare Foy (Director – Global Market Access, Mtech Access) interviewed Don Husereau (Adjunct Professor of Medicine, The University of Ott…

1
Rare Disease market access in the MENA and Nordic regions 59:10

7M ago59:10

59:10

Where will you be launching your new orphan medicine? You may be confident that your Global market access strategy will support access in key launch markets like the UK, the EU4 and the US, but have you thought about other markets? Have you looked at the reimbursement requirements for rare disease products in the Nordic markets? Have you explored o…

1
How does funding flow in NHSE Regions? 1:00:15

8M ago1:00:15

1:00:15

Which decisions are made at Region level in the NHS in England? How do finances and funding work at this level? And how can industry best support and engage with Region leaders? We sit down with guest speaker Richard Smale (Interim Director of System Co-ordination, NHS England [NHSE] – South West) for an all-encompassing discussion that explored fi…

1
NHS policy for 2024/25: strategy and engagement in a world of uncertainty (recorded in Jan 2024) 1:02:06

8M ago1:02:06

1:02:06

What do we know about plans and policy for 2024/25? As the expected central operating plan had not materialised (at time of recording), and with a general election and a potential Labour government on the horizon, how can NHS and industry drive forward improvements and innovation? Host Robert Hull (Senior Consultant – NHS Insight & Interaction, Mte…

1
De-mystifying health economic model classifications and structures 1:00:28

8M ago1:00:28

1:00:28

What is health economic evaluation and which modelling approaches can be used to support market access activities? In this episode, our expert health economists explain the key strengths and limitations of the most common health economic modelling classifications and structures. Here, Hannah Gillies (Consultant – Health Economics) and Daniel MacDon…

1
Evidence strategy for Medical Technologies and Diagnostics 53:24

8M ago53:24

53:24

Here, our experts explore evidence strategies for medical devices, diagnostics and digital health technologies. Have you established the clinical and economic value of your medical device, diagnostic or digital technology? Do you have the evidence required to support your value proposition? Would a health technology assessment (HTA) route be approp…

1
How to set your Pharma or Medtech product up for success in the US market 43:06

9M ago43:06

43:06

How can you ensure your product is set up for success from early clinical trials right through to launch and commercialisation? In this Global Whispers webinar we explore best practice commercialisation strategy for healthcare products launching in the US market. Clare Foy (Director – Global Market Access, Mtech Access) speaks to Janice MacLennan (…

1
What's happening with specialised commissioning in the NHS? 1:00:08

9M ago1:00:08

1:00:08

What’s happening with specialised commissioning in the NHS? How likely is a delay in delegation to integrated care boards (ICBs)? How and what should Pharma and Medtech plan for amidst all this uncertainty? Malcolm Qualie (former Medicines Lead for Specialised Services, NHS England) speaks to David Thorne (Principal Associate, Mtech Access) to expl…

1
Berufsbegleitende Promotion – Fluch oder Segen, Dr. Thomas Staab? 36:46

10M ago36:46

36:46

In unserer neuesten Podcast-Folge begrüßen wir Dr. Thomas Staab – er ist nicht nur Experte in seinem Feld, sondern auch Autor eines inspirierenden Ratgebers zur berufsbegleitenden Promotion. Dieses Gespräch bietet einen seltenen Einblick in die vielschichtigen Gründe und Motivationen, die hinter der Entscheidung stehen, neben dem Beruf zu promovier…

1
Integrated care in NHS Wales – what can England learn from its neighbour? 56:24

10M ago56:24

56:24

What does it take to run a truly patient-centric integrated health system? What does the Welsh journey with integration tell us about the future for England? Paul Mears (CEO, Cwm Taf Morgannwg University Health Board) joins Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) to explore the integrated care model in Wales and th…

1
Market access in Italy: Reforms at AIFA 43:36

11M ago43:36

43:36

Clare Foy (Director – Global Market Access, Mtech Access) speaks to Italian market access expert Prof. Fabrizio Gianfrate (Professor of Health Economics and Outcomes Research [HEOR] and Ex-Payer) about the market access landscape in Italy, particularly regarding changes at the Agenzia Italiana del Farmaco (AIFA). We explore: - The nature of the Ita…

1
Unmet need in NHS primary care – How can industry best support PCN leaders? 1:00:44

12M ago1:00:44

1:00:44

Dr Farzana Hussain (GP Principal, The Project Surgery) and Prof. Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) explore the unmet needs of Primary Care Networks (PCNs) and how industry can best support primary care leaders and GPs as we head into winter, 2024 and beyond. Former ‘GP of the year’ and strategic influencer over prim…

1
Population health management: a community effort across health and life sciences 1:04:01

1y ago1:04:01

1:04:01

How can our community support NHS leaders to deliver a data-led, people-centric health service? Dr Mark Davies (Global Chief Health Officer, IBM) joins Prof. Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) to explore the power of data, the role of community and how the health and life sciences ecosystem can support the NHS’s popu…

1
Artificial intelligence (AI) in clinical trials: Implications for evidence synthesis and market access 39:54

1y ago39:54

39:54

How is Artificial Intelligence being used in the development of new medicines? What role can AI currently play in clinical trials? Where can AI bridge gaps and solve challenges? What could this mean for the future of market access? In this webinar, Dr George Magrath explains how his team at Lexitas are using AI in clinical trials in the field of op…

1
6 areas of UK health policy for Medtech to pay attention to 1:01:49

1y ago1:01:49

1:01:49

How is the UK political landscape evolving and what does this mean for Health Technology and Medical Device innovators? Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) speaks to William Lee (Head of Policy and Compliance, British Healthcare Trades Association [BHTA]) about health policy, regulation and its implications for…

1
Market access in the German speaking markets 57:59

1y ago57:59

57:59

Here we explore market access challenges in Germany, Austria and Switzerland. Clare Foy (Global Market Access Director – Mtech Access) speaks to Dr Stefan Walzer (CEO, President & Founder at MArS Market Access & Pricing Strategy GmbH) about the challenges and opportunities for reimbursement in the German-speaking markets. Clare and Stefan discuss: …

1
The role of nursing in driving digital change in the NHS 54:50

1+ y ago54:50

54:50

How are nursing professionals supporting the digital evolution in UK healthcare? How can new technologies be leveraged by front-line clinical teams to support improved patient care? And how can Medtech, Digital and Biotech innovators collaborate with the front-line nursing teams in the NHS to drive transformation? Prof. Phil Richardson (Chair and C…

1
Market access for digital therapies and digital medicines 42:18

1+ y ago42:18

42:18

In this Global Whispers webinar we explore market access for digital therapeutics. Clare Foy (Global Market Access Director – Mtech Access) speaks to Shefali Shah (Global VP, Market Value and Commercial Effectiveness – MindMaze) about the challenges and opportunities for digital therapies to gain market access and ultimately improve patient outcome…

1
A global market access journey in cannabinoid pharmaceuticals 53:47

1+ y ago53:47

53:47

What does it take to bring a cannabinoid pharmaceutical to market? We were delighted to welcome Michael Sassano (CEO – SOMAÍ Pharmaceuticals) as the first guest on our new Global Whispers webinar series. Michael shared with us his company’s experiences bringing new products to market, the challenges SOMAÍ Pharmaceuticals have faced and the lessons …

1
Wie sorgt die Schiedsstelle im Bereich des AMNOGs konkret für eine (finale) Preisfindung? 32:56

1+ y ago32:56

32:56

Die Schiedsstelle kann eine wichtige Institution im Bereich des AMNOGs sein, wenn sich die beiden Parteien nicht einigen können. Dabei stellen sich verschiedene Fragen: Wie wird die Höhe des zu Erstattungsbetrags festgelegt? Welche Schwierigkeiten gibt es dabei und was hat sich über die letzten Jahre verändert? Die StudentInnen der DHBW Lörrach sch…

1
Primary Care and ICBs – what is the next step in the integration journey? 1:01:17

1+ y ago1:01:17

1:01:17

How will changes to the structure of primary care impact decision making? How is the relationship between Integrated Care Boards (ICBs) and primary care stakeholders evolving? How will funding flows be impacted? Prof. Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) is joined by Tim Goodson (Executive Officer, Dorset General Pract…

1
Wie funktioniert die Preisverhandlung im Rahmen des AMNOG Verfahrens? 42:53

1+ y ago42:53

42:53

Welchen Preis eine neue Therapie haben soll, entscheidet sich im Rahmen einer festgelegten Verhandlung. Dabei spielen verschiedene Faktoren und Zielsetzung eine Rolle. Aber wer entscheidet bzw verhandelt über die Erstattungsbeträge und welche Probleme können bei der Verhandlung auftreten? StudentInnen der DHBW Lörrach stellen sich diesen Fragen und…

1
Data-led transformation in the NHS - partnering to optimise patient care 1:02:35

1+ y ago1:02:35

1:02:35

Is data the key to transforming healthcare systems and patient care? What are the top priorities for digital transformation leaders in the NHS? How can Pharma and Medtech companies partner with the NHS to share data, transform services, and find smarter, faster way to improve patient care? Prof. Phil Richardson (Chair and Chief Innovation Officer, …

1
Innovating for better health – research, collaboration and innovation in the NHS 57:56

1+ y ago57:56

57:56

How and where can innovation drive improvements in care and deliver better health for the population? How is the NHS looking to collaborate with key partners across industry and academia? What innovations are set to transform care? What role do Academic Health Science Networks (AHSNs) play and how can partners best engage with them? Prof Phil Richa…

1
Welche Spezifika existieren bei der Bewertung von pädiatrischen Arzneimitteln im Bereich des AMNOG? 50:42

1+ y ago50:42

50:42

Der Gemeinsame Bundesauschuss (G-BA) ist auch für die Nutzenbewertungen von pädiatrischen Arzneimitteln zuständig. Spezifika bei diesen Medikamenten existieren allerdings nicht erst bei der Nutzenbewertung, sondern bereits im Vorfeld: Was haben Ethikkommission, Studienrekrutierung und Evidenztransfers von Studien mit Erwachsenen hierbei zu tun? Und…

1
Wie entscheidet der GBA über den Zusatznutzen von neuen Behandlungsoptionen im Mammakarzinom? 23:56

2y ago23:56

23:56

Der GBa (Gemeinsamer Bundesausschuss) ist für die Zusatznutzenbewertung von neuen Therapien in Deutschland zuständig. Darauf basierend verhandeln anschließend der pharmazeutische Unternehmer und der Spitzenverband der gesetzlichen Krankenkassen den Erstattungsbetrag. Doch wie trifft der G-BA seine Entscheidungen über den Zusatznutzen? Was sind dafü…

1
Healthcare, economics and society – unlocking NHS collaboration 59:23

2y ago59:23

59:23

Will NHS leaders, as part of an Integrated Care System (ICS), make conscious decisions to drive economic and social change? What social and economic value do ICSs offer the wider population they serve? How will industry support ICSs to deliver population-based health and social benefits? Prof Phil Richardson (Chair and Chief Innovation Officer, Mte…

1
Diabetes Mellitus und das deutsche AMNOG Verfahren - kann das funktionieren? 24:09

2y ago24:09

24:09

In dieser Folge des Next Gen Market Access Podcasts geben Studentinnen einen Überblick über die Möglichkeiten und Herausforderungen in der Erstattung von (neuen) Diabetes Therapien in Deutschland. Welche Formen von Diabetes existieren? Welche medikamentösen Therapien gibt es? Für die Erstattung muss der Hersteller durch das bekannte AMNOG Verfahren…

1
Specialised Commissioning in the NHS – What do you need to know now 1:00:34

2y ago1:00:34

1:00:34

The proposed new NHSE systems for specialised commissioning are arguably the highest risk of all current dynamics, both for the NHS and for suppliers. Key aspects or policy have been published in ways that are hard to access and even harder to interpret. Here, we gather an expert panel to discuss what proposed new NHSE systems for specialised commi…

1
Why are we waiting? - Pressures facing the NHS and how to deliver change 1:00:47

2y ago1:00:47

1:00:47

With so many patients left waiting for NHS care, what will the long-term impact be? How can Pharma and Medtech support the NHS with systematic challenges, like waiting? Where can industry work with the NHS to improve patient flow to get people appropriate treatment sooner and limit the harm caused by waiting? Prof Phil Richardson (new Chief Innovat…

1
Was sind ATMPs und wie werden diese erstattet? 31:10

2y ago31:10

31:10

Mit ATMPs (Advanced Therapy Medicinal Products) sind Therapien für Krankheiten möglich, die noch vor wenigen Jahren als unheilbar galten. Aber welche Evidenzbasis haben diese und wie wird damit auf Erstattungsebene umgegangen? Was gibt es besonderes bei diesen speziellen Therapien zu beachten? Die Studenten der DHBW Lörrach Lukas Kieffer, Alessio L…

1
Was passiert, wenn es Probleme in der Preisfindung für DIGAs gibt? 29:00

2y ago29:00

29:00

Digitale Gesundheitsanwendungen (DIGAs) kommen mehr und mehr im Alltag von Ärzt:Innen und Patient:Innen an. Wie sieht jedoch eine angemessene Preisgestaltung für DIGAs aus und was passiert, wenn GKV und Hersteller der DIGAs sich nicht einig werden? Dann kommt die Schiedsstelle ins Spiel. Im heutigen Next Gen Market Access Podcast erklären die Stude…

1
Helfen digitale Gesundheitsanwendungen im Bereich der Hormone und Stoffwechsel? 38:43

2y ago38:43

38:43

Die seit 2020 in Deutschland verfügbaren DIGAs bieten auch für Erkrankungen im Bereich der Hormone und Stoffwechsel neue Möglichkeiten. Angesichts der Tatsache, dass jeder 11. Erwachsene in Deutschland unter Diabetes leidet und jeder 4. Erwachsene adipös ist, gibt es hier ein großes Feld für digitale Innovationen. Die Studentinnen Moana Hösch, Juli…

1
Priority setting in primary care - NHS insights 59:35

2y ago59:35

59:35

How is the NHS balancing competing challenges as we head through integration and towards winter? How are priorities set and what does system planning look like in primary care? Dr Alex Degan (Primary Care Medical Director, Devon Integrated Care System [ICS]) joins Tom Clarke (Director, Mtech Access) to explore all this and more. In this episode, we…

1
Helfen digitale Gesundheitsanwendungen wirklich bei Angst- und Panikstörungen? 36:50

2y ago36:50

36:50

DiGAs sind seit 2020 verfügbar, viele im Bereich der seelischen Gesundheit. Aber wie sieht die Evidenzlage und Anwendung wirklich aus? Was sagt die junge Generation zu dieser Therapie „der zukunft“? Bei der ersten Folge des Next Gen Market Access Podcasts sprechen die Student:innen Aline Ezelsberger, Annalena Birkle, Jonas Jost und Noel Steinhilper…

1
Integrated Care Systems go live in the NHS - reflections after 3 weeks 1:00:21

2+ y ago1:00:21

1:00:21

On 1st July we saw the introduction of legislation for Integrated Care Systems (ICSs) in the NHS. In the weeks since, what has changed for healthcare leaders, practitioners and patients? What are the key priorities for NHS decision-makers and what is getting in the way of change? How can Pharma and Medtech support their NHS customers as they implem…

1
Clinical Pharmacists – exploring the scope, capabilities, and potential of this evolving NHS role 1:00:46

2+ y ago1:00:46

1:00:46

What roles and responsibilities do Clinical Pharmacists have in the NHS? How can Pharma and Medtech engage Clinical Pharmacists, and how can industry best support these new decision-makers? Tom Clarke (Director, Mtech Access) explores all this and more with Tom Kallis (Senior Clinical Pharmacist, East Cornwall PCN). They explore the origins of the …

1
Transforming systems and care pathways for an integrated NHS 1:00:47

2+ y ago1:00:47

1:00:47

As the NHS takes steps towards a more integrated future, how are systems and care pathways transforming? How is change being implemented, and what does this look like in reality for local systems and populations? Tom Clarke (Director, Mtech Access) explores all this and more with Debbie Morgan, (Director of Service Improvement and Transformation, C…

1
Digital value payer communication tools: How to meet the needs of your internal stakeholders and customers 39:25

2+ y ago39:25

39:25

Our experts in health economics, value communication, design and digital discuss how to craft digital payer value communication tools to meet the needs of internal stakeholders, including market access teams and KAMs, and healthcare customers. What does a best-in-class value communication tool look like in 2022? What are the key considerations when…

1
Population to Person: How will the NHS translate population health management into impactful, person-centred service change? 56:04

2+ y ago56:04

56:04

What does population health management mean for the NHS, for patients, and for industry? How will the NHS translate population health management into impactful service change and what will this look like for patients? Tom Clarke (Director, Mtech Access) explores all this and more with guest speaker Dr Steven Laitner (GP, Parkbury House Surgery). St…

1
Planning in a volatile environment: how will the NHS reconcile its competing priorities and operational planning to meet its challenges? 59:25

3y ago59:25

59:25

What does the ‘2022/23 priorities and operational planning guidance’ document mean for the NHS, for Integrated Care System (ICS) development and for an NHS workforce still battling COVID? How realistic and achievable are the priorities set out, and how can Pharma and Medtech best help NHS leaders to achieve these goals? Caroline Dawe (Deputy Direct…

1
The evolving NHS: How can Pharma and Medtech support the NHS in 2022? - NHS Insights Panel Discussion 1:02:57

3y ago1:02:57

1:02:57

Pharma and Medtech professionals put questions to our panel of NHS associates as we reflected on the operational, structural, and clinical challenges the NHS has faced in 2021 and how Pharma and Medtech can best support the NHS in 2022. We were joined by some of Mtech Access’s closest and most insightful friends: - David Thorne (Director, Mtech Acc…

1
Optimising the NHS – How will medicines be valued in integrated systems? 54:03

3y ago54:03

54:03

How will medicines be valued in the newly integrated world of the NHS? What are the risks and benefits of a single national formulary? What else is changing? And what does this mean for market access? Ellen Rule (Programme Director of the Gloucestershire Integrated Care System [ICS] and Director of Transformation and Service Redesign, Gloucestershi…

1
Rare disease market access - strategic and tactical challenges facing orphan medicines entering Europe 1:00:49

3y ago1:00:49

1:00:49

We explore the challenges facing orphan medicines and other innovative rare disease treatments looking to achieve market access in Europe. Orphan medicines and rare disease treatments are faced with a complex, ever-changing market landscape. These treatments also face unique tactical challenges on the route to securing market access. Here we bring …

1
A new paradigm for the NHS: Partnering to deliver lasting and meaningful care improvements - with Dr Phil Webb (Chief Executive of Respiratory Innovation Wales) 59:33

3y ago59:33

59:33

How are healthcare systems looking differently at their population to deliver better care and what does this mean for future decision-making? How might the NHS re-imagine the hospital? What benefits can we expect from novel technologies, and can the NHS develop system resilience to improve healthcare outcomes? Dr Phil Webb (Chief Executive of Respi…

Podcast đáng để nghe

Podcast Market Access

Podcast đáng để nghe

Hướng dẫn sử dụng nhanh